Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2016 | Predicting and diagnosing TB and CMV in hematopoietic cell transplant recipients

Roy Chemaly • 4 Apr 2016
EBMT 2016
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia

Roy Chemaly, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, USA, provides an overview of an symposium on the role of tuberculosis (TB) and cytomegalovirus (CMV) immunodiagnostics in hematopoietic cell transplant recipients. The theme of the symposium was to look at immunotesting, specifically the T-SPOT.TB and T-SPOT.CMV assays, and how they can help to better predict and diagnose TB and CMV in patients.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.

More from Roy Chemaly

2:30
Novel agents for CMV treatment in allo-HSCT recipients
Roy Chemaly • 8 Mar 2021
2:21
Cell-mediated immunity monitoring for CMV in HSCT patients
Roy Chemaly • 8 Mar 2021
2:30
Presatovir for HSCT recipients with RSV infection
Roy Chemaly • 8 Mar 2021
1:22
REACT: ELISPOT assay predicts CMV reactivation in allo-HSCT patients
Roy Chemaly • 8 Mar 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals